Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04910022 · ClinicalTrials.gov registry record · Phase 1

Ph I/II Study of NMS-03305293+TMZ in Adult Patients With Recurrent Glioblastoma

A Phase 1 study of Glioblastoma and Diffuse Glioma, sponsored by Nerviano Medical Sciences.

Active
Registry status
Phase 1
Development phase
150
Enrollment target
18
Study locations

NCT04910022 is a Phase 1 study of Glioblastoma and Diffuse Glioma that is active but no longer recruiting, run by Nerviano Medical Sciences. The registered enrollment target is 150 participants, above the 108-participant average among 199 other Glioblastoma trials with a reported enrollment target (39% higher). The trial reports 18 study locations across 11 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04910022, a Phase 1 study of Glioblastoma and Diffuse Glioma, is active but no longer recruiting, sponsored by Nerviano Medical Sciences.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
150 participants
Enrollment target
18
Study locations

Study Summary

Multicenter, open-label, single-arm Phase 1/2 study on the safety and efficacy of the combination of NMS-03305293 and temozolomide (TMZ) in adult patients with diffuse gliomas (Phase 1) and isocitrate dehydrogenase (IDH) wild type glioblastoma (Phase 2) at first relapse.

Conditions Studied

Glioblastoma Diffuse Glioma

Interventions

  • DRUG Temozolomide
  • DRUG NMS-03305293

Study Locations (18)

Other

  • IRCCS Istituto delle Scienze Neurologiche di Bologna - Bologna
  • IRCCS Istituto Neurologico Carlo Besta - Milan
  • Istituto Oncologico Veneto - IRCCS - Padua
  • Istituto Clinico Humanitas - Rozzano
  • Erasmus Medical Center - Rotterdam
  • PanOncology Trials (Pan American Center for Oncology Trials, LLC) - Rio Piedras
  • University Hospital Zurich - Zurich

Texas

  • UT Southwestern Medical Center - Dallas
  • The University of Texas MD Anderson Cancer Center - Houston

Arizona

  • Mayo Clinic Hospital - Phoenix - Phoenix

California

  • University of California Irvine Medical Center (UCIMC) - Chao Family Comprehensive Cancer Center - Orange

Florida

  • Mayo Clinic Florida - Jacksonville

Massachusetts

  • Dana-Farber Cancer Institute - Boston

Minnesota

  • Mayo Clinic Cancer Center - Rochester

New York

  • Memorial Sloan-Kettering Cancer Center - New York

Trial Details

FieldValue
Enrollment Target 150 participants
Start Date 2021-12-01
Est. Completion 2027-09-07
Phase Phase 1

Sponsor

Nerviano Medical Sciences

11 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT04910022

The ClinicalTrials.gov registry entry for NCT04910022 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 108-participant average among 199 other Glioblastoma trials with a reported enrollment target (39% higher). The listed sponsor is Nerviano Medical Sciences, which has 11 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Glioblastoma appearing as the primary indexed condition, and to 2 interventions - of which Temozolomide is the first listed.

NCT04910022 reports 18 study locations spanning 11 distinct geographic areas - top geographies include Other, Texas, Arizona.

Frequently Asked Questions

What is clinical trial NCT04910022 about?

NCT04910022 is a clinical study titled "Ph I/II Study of NMS-03305293+TMZ in Adult Patients With Recurrent Glioblastoma". Multicenter, open-label, single-arm Phase 1/2 study on the safety and efficacy of the combination of NMS-03305293 and temozolomide (TMZ) in adult patients with diffuse gliomas (Phase 1) and isocitrate dehydrogenase (IDH) wild type glioblastoma (Phase 2) at first relapse.

What is the current status of trial NCT04910022?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 150 participants. The study started on 2021-12-01. Estimated completion is 2027-09-07.

What conditions does trial NCT04910022 study?

This clinical trial studies the following conditions: Glioblastoma, Diffuse Glioma.

What interventions are being tested in trial NCT04910022?

The interventions under investigation include: Temozolomide (DRUG), NMS-03305293 (DRUG).

Who is sponsoring clinical trial NCT04910022?

This trial is sponsored by Nerviano Medical Sciences, which has 11 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04910022 being conducted?

This trial has 18 study locations across Arizona, California, Florida, Massachusetts, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Glioblastoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Glioblastoma

All registered trials for this condition

Diffuse Glioma

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.